The six-minute walk test is one of the most familiar assessments in clinical research. A participant walks for six minutes. Someone records the distance. The result is simple to explain and simple to compare.
That simplicity is its strength. It is also its limit. A single walk on a single clinic day says little about how someone moves at home, how quickly they tire or how their mobility changes between visits.
Wearable sensors do not replace the test. They add information during it and between visits.
What Is the Six-Minute Walk Test?
The six-minute walk test (6MWT) measures the distance a person can walk on a flat, hard surface in six minutes. The American Thoracic Society (ATS) published guidelines for the six-minute walk test in 2002, describing a self-paced walk back and forth along a straight corridor, with standardized instructions and encouragement.
The ATS guideline names measuring the response to medical interventions in patients with moderate to severe heart or lung disease as the test’s strongest indication. Clinical trials also use it in other conditions where walking ability matters, including rare neuromuscular conditions. It is familiar to sites, needs little equipment and is easy for participants to understand.
How Is the 6MWT Conducted?
The ATS guideline sets out a standard procedure so that results can be compared between visits and between sites.
The Course
The test is performed indoors, along a long, flat, straight, enclosed corridor with a hard surface that is seldom traveled. The guideline specifies a 30-meter walking course, so a 100-foot hallway is required. Turnaround points are marked with cones. The guideline does not recommend using a treadmill for the test.
Before the Walk
The participant sits at rest in a chair near the starting position for at least 10 minutes before the test starts. Participants use their usual walking aids, such as a cane or walker. When a test is repeated, the guideline advises running it at about the same time of day to minimize variability within the day.
Instructions and Encouragement
The participant is told that the object of the test is to walk as far as possible for six minutes, and that they are permitted to slow down, stop and rest as necessary. The person running the test does not walk with the participant. At the end of each minute, they say one of a set of scripted phrases, such as “You are doing well. You have 5 minutes to go.” The guideline advises against any other words of encouragement or body language to speed the participant up.
What Is Recorded
The main result is six-minute walk distance (6MWD). The worksheet also records the number of laps, heart rate, oxygen saturation (SpO2) and the participant’s ratings of breathlessness and fatigue on the Borg scale. If the participant stops early, the worksheet notes the distance, the time stopped and the reason for stopping.
Practice Tests
The 2002 guideline states that a practice test is not needed in most clinical settings but should be considered, and that performance usually reaches a plateau after two tests done within a week. A later technical standard on field walking tests from the European Respiratory Society (ERS) and ATS, published in 2014 for chronic respiratory disease, recommends performing two tests and recording the best distance when the 6MWT is used to measure change over time or response to treatment. Protocol teams need to confirm which standard applies to their population.
What Does the Six-Minute Walk Test Measure?
The 6MWT measures functional exercise capacity: how far a person can walk under standardized test conditions. Its primary output is six-minute walk distance.
The test is self-paced. The ATS guideline describes it as an assessment of the submaximal level of functional capacity, and notes that most patients do not reach maximal exercise capacity during the walk. Because most daily activities are performed at submaximal levels of exertion, the guideline suggests the distance may better reflect the functional exercise level for daily physical activities.
The guideline also describes the test as evaluating the global and integrated responses of all the systems involved during exercise, including the pulmonary and cardiovascular systems, circulation, blood, neuromuscular units and muscle metabolism. That breadth has a limit. The 6MWT does not determine peak oxygen uptake, diagnose the cause of breathlessness on exertion, or evaluate the causes or mechanisms of exercise limitation.
What Can a Single In-Clinic Test Miss?
A single in-clinic 6MWT shows what a participant can do on one day, in one setting, under test conditions. It does not show other days, how walking changes within the six minutes, or how the participant moves in daily life.
One Day, One Setting
A clinic test captures performance on the day of the visit. A good day or a bad day can shift the result.
Effort and Encouragement
Performance depends partly on motivation and on how the test is administered. Standardized instructions help, but they cannot remove every source of variation.
How Fatigue Builds During the Walk
Distance alone does not show how walking changes over the six minutes. Two participants can cover the same distance with very different patterns of slowing.
Life Between Visits
The test does not show how a participant moves at home, on a typical day, over weeks.
The Burden of Getting There
Travel to a site can be tiring in itself, particularly for people with limited mobility or for families managing a child with a rare condition.
What Do Wearable Sensors Add During the Test?
Sensors worn during a 6MWT can capture how a participant walks, not just how far. That includes gait characteristics such as cadence, the number of steps per minute.
Cadence recorded across the six minutes can show how walking changes as the test goes on. That pattern can be used to describe fatigability, which a single distance number does not show.
A Hypothetical Example
Consider two hypothetical participants who walk the same distance. The first holds a steady cadence for all six minutes. The second starts faster, then slows over the final two minutes. Their walk distances match, but their cadence profiles describe two different experiences of the same test. A sensor-supported protocol can record that difference, and the statistical analysis plan can define in advance whether and how it is analyzed.
What Do Wearable Sensors Add Between Clinic Visits?
Worn at home, sensors can capture habitual, real-world physical behavior: how much a participant walks, at what cadence and how that changes over time.
Real-world data answers a different question from the clinic test. The 6MWT shows what someone can do under test conditions. Real-world measures show what they actually do in daily life. Both can be relevant to a trial, and a study can plan to collect them together. In June 2024, VivoSense presented a longitudinal study on measuring physical function with wearable sensors in oncology, examining how real-world physical behavior captured by sensors relates to established measures of function.
Between-visit data only helps if there is enough of it. The protocol needs to define in advance how much wear makes a usable day, as set out in wear time, valid days and analyzable data.
Best 6-Minute Effort (B6ME™)
VivoSense has described a measure called Best 6-Minute Effort (B6ME™). It is a passive assessment of effort derived from high-resolution wrist-actigraphy data. B6ME is measured daily in a patient’s own environment, and patients receive no instructions other than to perform their typical daily routine.
B6ME is a real-world measure. It adds to the in-clinic six-minute walk test rather than replacing it.
In-Clinic vs Sensor-Supported Assessment
| In-clinic 6MWT | Sensor-supported assessment | |
|---|---|---|
| Setting | Clinic or research site | Clinic, plus home when worn between visits |
| Frequency | At scheduled visits | At visits, plus continuous or daily data |
| Instructions | Standardized script and encouragement | Test script in clinic, typical daily routine at home |
| Main output | Distance walked | Distance, plus gait measures such as cadence |
| Fatigue during the test | Not captured by distance alone | Cadence patterns across the six minutes |
| Daily life | Not captured | Habitual real-world physical behavior |
A Published Example: Congenital Myasthenic Syndromes
A VivoSense case study, published in July 2026, describes a Phase 1b study evaluating ARGX-119 in 16 patients with congenital myasthenic syndromes (CMS), specifically the DOK7 variant.
The case study describes “DHT-enabled gait analysis during the Six-Minute Walk Test (6MWT),” where DHT stands for digital health technology. The case study reports “the clinically meaningful increase observed in Six-Minute Walk Test performance among ambulatory participants,” and that “Investigators observed improvements in both total walking distance and cadence.”
It also reports that “VivoSense analyzed cadence patterns throughout the 6MWT to quantify fatigability,” that “Researchers also observed strong correlations between in-clinic walking cadence and real-world mobility performance,” and that “habitual real-world cadence improved alongside in-clinic measures.”
On participant experience, “100% of participants reported a willingness to use digital health technology again in future clinical trials.”
These findings come from one Phase 1b study in one rare condition. The walk test results belong to the ARGX-119 study, and a correlation is not clinical validation. The study shows how in-clinic and real-world measures can be designed to work together. Read the ARGX-119 CMS case study. Rare disease programs raise further design questions, covered in digital endpoints in rare disease clinical trials.
Planning a Sensor-Supported Walk Test
Planning can follow the same five stages used to develop digital endpoints.
Identify a Meaningful Clinical Concept
Start with what matters to patients, such as the ability to walk and move through daily life.
Select Appropriate Technologies
Choose sensors suited to the disease state and the population of the patients, and to both in-clinic and at-home use if the study needs both. The considerations are set out in how to select wearable sensors for a clinical trial.
Develop Digital Biomarkers
Define the measures derived from sensor data, such as cadence during the test or daily walking in real life, and how each will be computed. The terms are defined in what are digital biomarkers.
Establish Validation Evidence
Plan the evidence each measure needs for its role in the trial and its context of use. The U.S. Food and Drug Administration (FDA) final guidance on digital health technologies for remote data acquisition, announced in December 2023, carries nonbinding recommendations on the verification and validation of DHTs and on using DHTs to collect data for trial endpoints. The evidence types are explained in digital measure validation and the V3 framework.
Build Digital Endpoints
Set out how the measures will be analyzed and how they relate to the 6MWT and to each other. A digital biomarker is the measurement, and a digital endpoint is the trial outcome built from it, as explained in digital biomarkers vs digital endpoints.
A Planning Checklist
- Which 6MWT standard the protocol follows
- Whether practice tests are included
- Which gait measures are captured during the test, and why
- Whether sensors are worn between visits, and for how long
- What counts as a valid day of real-world data
- How sensor measures relate to walk distance in the analysis plan
- What participants are asked to do at home, and what support they receive
Common Mistakes
Adding Sensors Without a Question
Collecting gait data during a walk test without a defined purpose creates data nobody plans to analyze.
Treating Correlation as Validation
A correlation between in-clinic and real-world measures is useful evidence. It is not clinical validation on its own.
Letting the Test Procedure Drift
The ATS guideline standardizes the course, the script and the timing of repeat tests to limit variability. Sensor data collected during a test that drifts from its own protocol inherits the same problem.
Ignoring Participant Burden
At-home wear adds a task to a participant’s day. Devices, wear schedules and support should reflect what participants can realistically sustain. Participant experience also covers what participants get back from a study, a topic VivoSense has published on in sharing wearable sensor data with participants.
Six-Minute Walk Tests With VivoSense
VivoSense is a wearable sensor contract research organization (CRO) that works alongside the sponsor’s trial team and CRO on the digital measurement workstream. It helps choose the right device based on the disease state and the population of the patients, chooses what measures to capture, ships devices and trains sites, monitors real-time wear compliance, and delivers formatted regulatory-ready data packages for the study team.
VivoSense was founded in 2010.
Frequently Asked Questions
What is the 6MWT?
The six-minute walk test (6MWT) measures the distance a person can walk on a flat, hard surface in six minutes. The American Thoracic Society published guidelines for it in 2002, and it is widely used as an outcome in clinical trials.
What does the six-minute walk test measure?
It measures functional exercise capacity. The main output is six-minute walk distance. Sites also record laps, heart rate, oxygen saturation, and ratings of breathlessness and fatigue.
How long is the course for a six-minute walk test?
The 2002 ATS guideline specifies a 30-meter course along a flat, straight, enclosed corridor, with turnaround points marked by cones. It does not recommend a treadmill.
Is the six-minute walk test a maximal exercise test?
No. The test is self-paced and assesses the submaximal level of functional capacity. The ATS guideline notes that most patients do not reach maximal exercise capacity during the walk.
Can wearable sensors be used during a 6MWT?
Yes. Sensors can capture gait characteristics such as cadence during the test, including how walking changes over the six minutes.
What is the difference between the 6MWT and real-world mobility measures?
The 6MWT shows what someone can do under test conditions on a single day. Real-world mobility measures show what they do in daily life over time.
Do wearable sensors replace the six-minute walk test?
No. They add information during the test and between visits. Studies can plan the two to work together.
Why use wearable sensors in rare disease walk tests?
Clinic travel is a burden for many participants with rare conditions. Sensor data can add detail during the test and between visits without adding clinic visits.
Let’s Talk
Schedule a consultation to explore how to design and use validated digital measures in your clinical trials.
Book A Meeting